Multiple Myeloma
A plasma-cell hematologic malignancy, treated with induction, autologous transplant where eligible, and continuous/maintenance therapy across proteasome inhibitor, IMiD, anti-CD38, and (increasingly) bispecific/CAR-T drug classes.
Phase 1/2 and later readouts in Multiple Myeloma, in your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Coverage in progress. AssetMemo has not yet run its full census for Autologous Stem Cell Conditioning in Multiple Myeloma, so the assets listed for it are not complete.
Combined attributable cost
$11.1B+
Drug spend
Not yet sourced
Sum of 2 indications below.